Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2,Double-Blind,Randomized Clinical Trial to Explore the Safety,Tolerability,Efficacy, and Pharmacokinetics of PRAX-562 in Pediatric Participants With Developmental and Epileptic Encephalopathies Followed by Open-Label Extension(OLE)

NCT05818553 is registered in ClinicalTrials.gov with Praxis Precision Medicines as lead sponsor.

NCT NCT05818553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05818553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2,Double-Blind,Randomized Clinical Trial to Explore the Safety,Tolerability,Efficacy, and Pharmacokinetics of PRAX-562 in Pediatric Participants With Developmental and Epileptic Encephalopathies Followed by Open-Label Extension(OLE)
Lead sponsor
Praxis Precision Medicines
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
August 2, 2023
Completion date
March 1, 2027
Enrollment
77 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

scn2a encephalopathy, scn8a encephalopathy